Conference Proceedings
Efficacy of immune checkpoint inhibitors (ICIs) for in-transit melanoma.
Emilia Nan Tie, Julia Elizabeth Lai-Kwon, Lumine Na, Michael Alexander Rtshiladze, James Bozzi, Tavis Read, Victoria Atkinson, George Au-Yeung, Georgina V Long, Grant A McArthur, Shahneen Kaur Sandhu, Robyn Saw, Euan Thomas Walpole, Alexander M Menzies, B Mark Smithers, David E Gyorki
JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2019
Abstract
9583 Background: The efficacy of ICIs in metastatic melanoma is well-established. However, there is limited data regarding their efficacy in in-transit melanoma metastases (ITM). This study assessed the efficacy of ICI in patients with ITM. Methods: A multisite, retrospective review of patients with ITM treated with ICI from 2004-2018. Demographic and clinicopathological factors (age, sex, primary site, AJCC version 8 stage, BRAF status, prior locoregional therapies) were collected. Objective response rate (ORR) based on a clinician-assessed best overall response, progression free survival (PFS) and overall survival (OS) were analyzed by the Kaplan-Meier method. Results: Fifty-four patients..
View full abstract